PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Completed

Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC

Interventions: Drug: dacomitinib hydrate

First Posted Date: 2019-11-07

Last Posted Date: 2025-05-23

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT04155541

Locations: 🇯🇵
Pfizer Japan, Tokyo, Japan

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Melanoma Cancer
Gastric Cancer
Pancreatic Cancer
Esophageal Cancer
Bile Duct Cancer
Endometrial Cancer
Renal Cell Carcinoma
Lung Squamous Cell Carcinoma
Ovarian Cancer

Interventions: Drug: PF-06940434
Drug: PF-06801591

First Posted Date: 2019-11-05

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 85

Registration Number: NCT04152018

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 28 locations

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07081532

First Posted Date: 2019-11-01

Last Posted Date: 2020-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT04148209

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06826647
Drug: Oral Contraceptive (OC)

First Posted Date: 2019-10-22

Last Posted Date: 2020-02-05

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04134715

Locations: 🇺🇸
Quotient Sciences-Miami, Miami, Florida, United States
🇺🇸
Quotient Sciences Screening Office, Coral Gables, Florida, United States

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Phase 1

Completed

Conditions: Dermatitis Atopic

Interventions: Drug: PF-07038124 or vehicle
Drug: PF-07038124 and Vehicle

First Posted Date: 2019-10-22

Last Posted Date: 2020-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT04135560

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

Phase 2

Terminated

Conditions: Gram-negative Bacterial Infection

First Posted Date: 2019-10-14

Last Posted Date: 2024-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT04126031

Locations: 🇬🇷
"ATTIKON" University General Hospital, Chaidari, Athens, Greece
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Tufts Children's Hospital at Tufts Medical Center, Boston, Massachusetts, United States

and more 15 locations

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Phase 1

Withdrawn

Conditions: Pharmacokinetics

Interventions: Drug: bevacizumab - EU
Drug: PF-06439535 (CN)

First Posted Date: 2019-10-14

Last Posted Date: 2021-04-27

Lead Sponsor: Pfizer

Registration Number: NCT04126044

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Relative Bioavailability
Drug: PF-06842874
Drug: Placebo

First Posted Date: 2019-10-11

Last Posted Date: 2021-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT04124653

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Completed

Conditions: Metastatic Renal Cell Carcinoma ( mRCC)

Interventions: Drug: Sunitinib

First Posted Date: 2019-10-03

Last Posted Date: 2022-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 57

Registration Number: NCT04115189

Locations: 🇧🇷
Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil
🇦🇷
Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina
🇦🇷
Sanatorio del Salvador - Cordoba, Cordoba, Argentina

and more 4 locations

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tofacitinib tablet
Drug: Tofacitinib Oral Solution

First Posted Date: 2019-10-01

Last Posted Date: 2020-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04111614

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy